LKB1-KO/Kras-G12D-Luc

Export PDF

Strain Information

Cell Line

LKB1-KO/Kras-G12D-Luc

Cat. NO.

NM-YD07

Model Description

derived from LKB1-KO/Kras-G12D-Luc mice spontaneous lung cancer model

Strain State

Validation of tumorigenic capacity completed

Validation Data

image.png

Fig1. The genotype of LKB1-KO/Kras-G12D-Luc cell was identified by PCR

WT: wild-type cells; H2O: negative water control; 100bp DNA marker from Transgen(BM311)

image.png

Fig2. Tumor growth curve in LKB1-KO/Kras-G12D-Luc subcutaneously transplanted tumor model (n=6)  

image.png

Fig3. Body weight change in LKB1-KO/Kras-G12D-Luc subcutaneously transplanted tumor model (n=6)

image.png

Fig4. Signal increase curve of LKB1-KO/Kras-G12D-Luc cells were implanted orthotopically in the lung (n=6)

image.png

Fig5. Body weight change in orthotopically injected LKB1-KO/Kras-G12D-Luc model (n=6)

image.png

Fig6. Survival curve of LKB1-KO/Kras-G12D-Luc orthotopic model (n=6)

image.png

Fig7. Bioluminescence imaging of LKB1-KO/Kras-G12D-Luc subcutaneously transplanted tumor model at different timepoints

image.png

Fig8. Bioluminescence imaging of LKB1-KO/Kras-G12D-Luc orthotopic model (n=6)

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more